INTRANASAL FORMULATIONS OF INTERFERON BETA FREE OF STABILIZERS THAT ARE PROTEINS OR POLYPEPTIDES

摘要

Compositions and methods are provided for intranasal delivery of interferon-ss yielding improved pharmacokinetic and pharmacodynamic results wherein the composition is free of a stabilizer that is a protein or a polypeptide. In certain aspects of the invention, the interferon-ss is delivered to the intranasal mucosa along with one or more intranasal delivery-enhancing agent(s) to yield substantially increased absorption and/or bioavailability of the interferon-ss and/or a substantially decreased time to maximal concentration of interferon-ss in a tissue of a subject as compared to controls where the interferon-ss is administered to the same intranasal site alone or formulated according to previously disclosed reports. The enhancement of intranasal delivery of interferon-ss according to the methods and compositions of the present invention allows for the effective pharmaceutical use of these agents to treat a variety of diseases and conditions in mammalian subjects.